Improvement of skin flap perfusion by subdermal injection of recombinant human basic fibroblast growth factor.
The effect of subcutaneously injected recombinant human basic fibroblast growth factor (bFGF) was studied in an arterial skin flap model on the ear of the hairless mouse. Fifty-three male, hairless mice were randomly assigned to 4 groups and pretreated in two different time intervals with different doses of human bFGF. Microvascular perfusion of the skin flaps was determined over a 5-day period by means of intravital microscopy after intravenous injection of the fluorescence marker fluorescein isothiocyanate-dextran (M(r) 150,000). Human bFGF (2,700 ng) injected 6 days before flap creation could not improve perfusion of the flap (n = 10) when compared with controls. However, when applied 18 days before flap creation (n = 13), the same dose resulted in a significant reduction of nonperfused tissue at day 5 after flap creation (12.3% vs 26.8%, p < 0.01). Eighteen-day pretreatment with 1,200 ng (n = 10) and 480 ng (n = 10) had no significant effect on skin flap perfusion. We conclude, therefore, that successful pretreatment with bFGF for prevention of skin flap necrosis is time and dose dependent.
Uhl
E
E
Institute for Surgical Research, Ludwig-Maximilians-University, Munich, Germany.
Barker
J H
JH
Bondàr
I
I
Galla
T J
TJ
Lehr
H A
HA
Messmer
K
K
D000818:Animals; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008812:Mice, Hairless; D010477:Perfusion; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage; D012867:Skin / Q000098:blood supply; D013524:Surgical Flaps
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2